ReviewJournal of clinical medicine2019
Blood-Based Treatments for Severe Dry Eye Disease: The Need of a Consensus.
Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 59 citations in OpenAlex.
- Acceptance of Allogeneic Serum Eye Drops Among Users of Autologous Serum Eye Drops-A Survey-Based Study.Journal of clinical medicine · 2026Article
- Article
- The Role of Innervation in Ocular Surface Homeostasis, Tissue Remodeling Following Nerve Injury, and the Therapeutic Potential of Hemocomponents in Neuronal and Cicatricial Pathologies.Journal of clinical medicine · 2026Review
- Development of Autologous Serum Ocular Insert for Chronic Dry Eye Disease.Pharmaceutics · 2026Article
- Safety and exploratory functional effects of topical cord blood serum in glaucoma patients.Scientific reports · 2026Article
- Cord Blood Serum Attenuates Hyperosmolarity-Induced Inflammation and TRPV1 Upregulation in Conjunctival Epithelial Cells.International journal of molecular sciences · 2026Article
- Allogeneic fresh frozen plasma eye drops for the treatment of ocular Graft-versus-Host disease: prospective open-label study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- CORONIS symposium 2023: Scientific and clinical frontiers in ocular surface innervation.Acta ophthalmologica · 2025Article
- Current and Emerging Therapeutic Strategies for the Management of Neurotrophic Keratitis.Drugs · 2025Review
- Autologous blood in the management of ocular surface disorders.World journal of experimental medicine · 2024Review
- Achieving net-zero in the dry eye disease care pathway.Eye (London, England) · 2024Review
- Severe Dry Eye Disease in Charcot-Marie-Tooth Disease: A Comprehensive Case Report.The American journal of case reports · 2023Article
- Use of allogeneic platelet-rich plasma for the treatment of autoimmune ocular surface disorders: case series.Frontiers in ophthalmology · 2023Article
- Neurotrophic keratopathy: current challenges and future prospects.Annals of medicine · 2022Review
- Effect of sodium hyaluronate eye drops combined with tobramycin, dexamethasone and pranoprofen eye drops in the treatment of dry eye after phacoemulsification.Indian journal of ophthalmology · 2022Article
- Impact of Freeze-Drying on Cord Blood (CB), Serum (S), and Platelet-Rich Plasma (CB-PRP) Preparations on Growth Factor Content and In Vitro Cell Wound Healing.International journal of molecular sciences · 2022Article
- Neurotization of the human cornea - A comprehensive review and an interim report.Indian journal of ophthalmology · 2022Review
- Impact of blood source and component manufacturing on neurotrophin content and in vitro cell wound healing.Blood transfusion = Trasfusione del sangue · 2022Article
- Long-term clinical outcome and satisfaction survey in patients with neurotrophic keratopathy after treatment with cenegermin eye drops or amniotic membrane transplantation.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Article
- Autologous Platelet-Rich Plasma Drops for Evaporative Dry Eye Disease from Meibomian Gland Dysfunction: A Pilot Study.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of blood-based eye drops as therapy for various diseases of the ocular surface has become increasingly popular in ophthalmic practice during recent years. The rationale for their use is based on the promotion of cellular proliferation and migration thanks to the supply of metabolically active substances, in particular growth factors. Blood-derived eye drops have been used for the treatment of several ocular surface disorders, such as dry eye disease, corneal ulcer, persistent epithelial defect, neurotrophic keratitis, ocular surface burn, recurrent corneal erosion, and limbal stem-cell deficiency. Both autologous (from patients themselves) and heterologous (from adult donors or from cord blood sampled at birth)-derived products exist, and each source has specific pros and cons. Despite an extensive literature, several issues are still under debate and the aim of this manuscript is to review the indications, preparation methods and storage, characterization of content, rationale for clinical outcomes, patient stratification, length of treatment, and rationale for repeated treatments at disease relapse. A rationale based on a "5 Ws and 2 Hs" protocol is proposed as a way of thinking, with the attempt to clarify Who, Why, When, Where, What, and How to use these treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.